Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Preclinical safety at tested doses has been reasonable, but human long-term safety data are not established
Journal of Cosmetic Dermatology, 19 (12), 3262-3269
Fruergaard Jrgensen acknowledged the criticism, particularly around the firm's failure to accurately communicate the flexible trial design, which raised questions over tolerability, with fewer than two-thirds of patients progressing to the highest dose after 68 weeks
In summary, you can expect: regular clinic visits and blood tests (IGF-1 and others) every few months initially
US$ 21.58
US$ 23.27
US$ 20.08
US$ 27.73
US$ 20.35
